Clinical development in Parkinson’s regeneration advanced as reports highlighted feasibility and early safety signals from stem-cell-derived dopaminergic cell transplantation. A Phase I/II open-label trial led by Lund University investigators (STEM-PD) reported no serious side effects tied to transplanted cells during the first year of follow-up, supporting continued clinical development in larger cohorts.